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Summary
Background As countries embark on public health-oriented drug law reform, health impact evaluations are needed. 
In 2012, Mexico mandated the narcomenudeo reform, which depenalised the possession of small amounts of drugs 
and instituted drug treatment instead of incarceration. We investigated the past and future effect of this drug law 
reform on HIV incidence in people who inject drugs in Tijuana, Mexico.
Methods In this epidemic modelling study, we used data from the El Cuete IV cohort study to develop a  deterministic 
model of injecting and sexual HIV transmission in people who inject drugs in Tijuana between 2012 and 2030. The 
population was stratified by sex, incarceration status, syringe confiscation by the police, HIV stage, and exposure to 
drug treatment or rehabilitation (either opioid agonist treatment or compulsory drug abstinence programmes). We 
modelled the effect of these exposures on HIV risk in people who inject drugs, estimating the effect of observed and 
potential future reform enforcement levels.
Findings In 2011, prior to the narcomenudeo reform, 547 (75%) of 733 people who inject drugs in the El Cuete cohort 
reported having ever been incarcerated, on average five times since starting injecting. Modelling estimated the limited 
reform implementation averted 2% (95% CI 0·2–3·0) of new HIV infections in people who inject drugs between 
2012 and 2017. If implementation reduced incarceration in people who inject drugs by 80% from 2018 onward, 
9% (95% CI 4–16) of new HIV infections between 2018 and 2030 could be averted, with 21% (10–33) averted if people 
who inject drugs were referred to opioid agonist treatment instead of being incarcerated. Referral to compulsory drug 
abstinence programmes instead of prison could have a lower or potentially negative impact with –2% (95% CI 
–23 to 9) infections averted.
Interpretation Mexican drug law reform has had a negligible effect on the HIV epidemic among people who inject 
drugs in Tijuana. However, appropriate implementation could markedly reduce HIV incidence if linked to opioid 
agonist treatment. Unfortunately, compulsory drug abstinence programmes are the main type of drug rehabilitation 
available and their expansion could potentially increase HIV transmission.
Funding National Institute on Drug Abuse, UC San Diego Center for AIDS Research. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Public health-oriented drug law reforms were 
implemented in the late 1990s and early 2000s in the 
Netherlands, Portugal, and Switzerland, and are currently 
being implemented in several countries including 
Mexico, Brazil, Paraguay, Uruguay, Colombia, Malaysia, 
Canada, and some US states.1 This move follows 
mounting evidence that criminalisation fails to reduce 
drug use, while fuelling crime, violence, and negative 
health outcomes at substantial economic cost.2 The 
harms of punitive drug policies disproportionately affect 
people who inject drugs. Incarceration and the period 
post-release have been associated with HIV, tuberculosis, 
hepatitis B and C, overdose, and mental health disorders 
in people who inject drugs.3 Additionally, policing 
practices including arrest, extortion, and syringe 
confiscation have been associated with increased risk of 
blood-borne infection transmission in people who inject 
drugs.4,5
Studies of the effect of drug law reforms on the health 
of people who inject drugs are needed, but very few 
assessments have been done in Latin America and 
other low-income and middle-income settings, despite 
growing momentum for such reforms.5 However, drug-
law reforms are complex structural interventions for 
which evaluation through community randomised 
controlled trials might be legally, ethically, or logistically 
difficult or unfeasible.6 Epidemic modelling is a useful 
method to address this limitation because it allows 
simulating control scenarios accounting for demo-
graphic and epidemic dynamics through time.7 Three 
modelling studies have assessed the contribution of 
incarceration to HIV, hepatitis C, and tuberculosis 
epidemics in people who inject drugs, but none have 
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evaluated the effect of drug law reform on disease 
incidence.2,8,9
In 2009, Mexico enacted drug and health law reforms 
(referred to as the narcomenudeo reform hereafter), 
which depenalised possession of small amounts of 
selected drugs for personal consumption (appendix p 1) 
and mandated drug treatment on the third apprehension 
under drug possession thresholds instead of in-
carceration.10 The northwest state of Baja California 
became subject to the full enforcement of the 
narcomenudeo reform in 2012. The state has the highest 
prevalence of past-year illicit drug use (4·4% vs 2·7% at 
the national level)11 and its largest city, Tijuana, on the 
Mexico–US border has an estimated 10 000 people who 
inject drugs.12 HIV prevalence in people who inject drugs 
was 3·5% in 2011, and incidence was 1·1 per 100 person-
years between 2011 and 2017.13 As recorded in other 
settings, people who inject drugs in Tijuana are often 
incarcerated or harassed by the police (eg, via syringe 
confiscation),13 exposures associated with receptive needle 
sharing.4,14 The narcomenudeo reform has the potential to 
reduce incarceration in people who inject drugs, and 
therefore prevent HIV transmission.
However, findings of early studies indicated little 
knowledge about the reform among the Tijuana police.15 
Affordable and quality evidence-based drug treatment 
services were scarce, and in 2014, government funds were 
allocated to compulsory drug abstinence programmes.16 
In Tijuana, these entail physically restraining individuals, 
brought involuntarily by family, friends or the police, in 
non-medically supervised centres over 3–6 months and 
subjecting them to non-evidence based interventions, 
often involving punishment, to achieve detoxification and 
abstinence.17 Given these contextual circumstances, the 
effect of the narcomenudeo reform implementation on 
the HIV epidemic in Tijuana is unclear. 
In 2011, the El Cuete IV cohort study18 recruited 
734 people who inject drugs through convenience 
sampling and has since provided biannual quantitative 
and periodic qualitative information about HIV, risk 
behaviours, and exposures to policing, incarceration, and 
harm reduction services in people who inject drugs 
(appendix p 1). It was designed to monitor and assess the 
effect of the drug law reform on these structural exposures 
in people who inject drugs, and provides a unique 
opportunity to inform an epidemic model to estimate its 
effect on HIV incidence.
 This epidemic modelling study, in which  we used data 
from the El Cuete IV study to assess the past and future 
effect of the narcomenudeo reform on HIV incidence in 
people who inject drugs in Tijuana, should serve as a 
case study to guide effective reform implementation in 
Mexico and other settings.
Methods
Epidemic model structure
We developed a dynamic deterministic compartmental 
model of injecting and sexual HIV transmission in 
Research in context
Evidence before this study
We reviewed the published literature on epidemic modelling of 
drug policy impact on health by searching PubMed on 
Jan 10, 2018, using the following search terms: (“drug* policy” 
OR “drug* policies” OR “drug* law*” OR “criminalization” OR 
“decriminalization” OR “incarceration” OR “prison”) AND 
(“health” OR “HIV” OR “HCV” OR “hepatitis” OR “tuberculosis” OR 
“Tuberculosis” OR “disease”) AND (“Model*”). We also searched 
for related articles in the references of selected articles. We did 
not apply restrictions by language or date of publication. 
Numerous studies modelled disease transmission (such as HIV, 
hepatitis B and C, or tuberculosis) within prison or in people who 
inject drugs. Three modelling studies explored the hypothetical 
effect of reduced incarceration on HIV and HCV epidemics in 
people who inject drugs, but were focused on settings without 
drug law reform (Altice, 2016; Csete, 2016; and Stone, 2017).
Added value of this study
To our knowledge, our epidemic modelling study is the first to 
assess the effect of a documented drug law reform on HIV 
incidence in people who inject drugs. It capitalises on data from 
a cohort study designed to investigate the effect of the Mexican 
drug law reform on HIV risk in people who inject drugs in 
Tijuana, the city with the highest estimated number of people 
who inject drugs in Mexico. The reform allows for the possession 
of selected drugs for personal consumption and mandates drug 
treatment at the third apprehension. Our findings suggest that, 
so far, the reform has only had a minor effect on HIV incidence 
because of its limited implementation. However, if properly 
implemented—such that 80% of people who inject drugs who 
would have been incarcerated received opioid agonist treatment 
instead—HIV incidence could be reduced by 21% (95% CI 10–33) 
between 2018 and 2030. Furthermore, less impact, or even 
harm, could occur if people who inject drugs were instead 
referred to compulsory drug abstinence programmes, the main 
type of drug rehabilitation available in Tijuana.
Implications of all the available evidence
Epidemic modelling, informed by longitudinal studies monitoring 
policing and incarceration exposures among people who inject 
drugs and associated risk, supports rigorous evaluations of the 
effect of drug law reforms on disease epidemics. Appropriately 
implemented drug law reform leading to reduced incarceration 
and referral to opioid agonist treatment could prevent HIV and 
related epidemics among people who inject drugs in Tijuana. This 
study is highly relevant to other cities in Mexico and Latin America 
that have HIV epidemics among people who inject drugs, as the 
rule of law is often weak across the region, hampering reform 
enforcement, and compulsory abstinence programmes are the 
main type of drug rehabilitation available and can cause harm.
See Online for appendix
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people who inject drugs, including incarceration and 
police harassment (via syringe confiscation; figure 1). 
The population was stratified by sex, incarceration 
stage, exposure to syringe confiscation in the past 
6 months, and HIV stage (figure 1). We neglected ART 
because coverage was less than 1% in HIV-infected 
people who inject drugs in Tijuana. The model was 
additionally stratified by exposure to drug treatment or 
rehabilitation (either opioid agonist treatment or 
compulsory drug abstinence programmes). Injecting 
and sexual transmission were represented through a 
system of coupled ordinary differential equations as 
functions of the number of syringe sharing events or 
sex acts, the probability of transmission through syringe 
sharing or by sex act and the HIV prevalence and HIV 
stage in partners. Syringe sharing contacts were 
assumed to follow random mixing. Sexual contacts were 
assumed to be exclusively hetero sexual and shared 
between people who inject drugs and non-injecting 
partners. Differences in number of sex acts and condom 
use with stable, casual, and commercial partners were 
represented. A relative risk of HIV infection through 
injecting in people who inject drugs exposed to recent 
syringe confiscation, compulsory drug abstinence 
programmes, opioid agonist treatment and recent 
incarceration was applied to reflect their effect on the 
frequency of receptive sharing events, based on data 
described in the next section (appendix p 5).
HIV co-infection models (in which the co-infection 
was transmitted only via sexual or injecting routes) have 
been successfully used to distinguish the relative 
contribution of sexual versus injecting risk on HIV in 
people who injected drugs. Therefore, to more accurately 
estimate the potential effect of interventions addressing 
injecting transmission, we also estimated the con-
tribution of sexual transmission to HIV incidence using 
a simplified model of HIV and syphilis co-infection 
(appendix pp 16–19).
Epidemic model parameterisation and calibration
The model was parameterised using demographic and 
HIV risk behaviour data from El Cuete IV and calibrated 
to HIV incidence and prevalence data by sex and 
incarceration history in people who inject drugs in 
Tijuana from 2005–15 (table 1). We used data from 
El Cuete IV to parameterise temporal trends in exposure 
to incarceration and police (recent [<6 months] incar-
ceration, recent [<6 months] syringe confiscation by the 
police). Additional prison demography parameters were 
estimated using a simplified cohort model calibrated to 
incarceration data from El Cuete IV (appendix pp 10, 11). 
The relative risk of receptive syringe sharing associated 
with these exposures was also estimated from 
El Cuete IV baseline (appendix p 5). Because we found 
no association between exposure to recent syringe 
confiscation and incarceration, or effect on receptive 
syringe sharing, we assumed these mechanisms 
operated independently. We also assessed temporal 
trends in current opioid agonist treatment use (yes or 
no) and recent (<6 months) exposure to compulsory 
drug abstinence programmes, as these are potentially 
related to the narcomenudeo reform provision for drug 
treatment. Because the pro portion exposed to recent 
compulsory drug abstinence pro grammes was very low 
A B C D E
Man Never incarcerated Syringe confiscation
(past 6 months)
Susceptible Never exposed 
to CAP
On OAT 
or 
Woman Prison 
Recently incarcerated
(<6 months ago) 
Not recently 
incarcerated
(>6 months ago) 
No syringe 
confiscation
(past 6 months)
Acute infection
Late infection 
Pre-AIDS 
AIDS 
Ever exposed 
to CAP
Off OAT 
Figure 1: Disaggregation of the people who inject drugs population
By (A) sex, (B) incarceration, (C) syringe confiscation, and (D) HIV status, and the flows and corresponding rates between states within each model dimension, and 
(E) OAT or CAP to which people who inject drugs are diverted to instead of incarceration under different enforcement scenarios of the Narcomenudeo reform as 
indicated by the red shading. OAT=opioid agonist treatment. CAP=compulsory abstinence programme. *In prison, no syringe confiscation by the police occurs 
because there is no interaction with the police and there is no access to either OAT or CAPs.
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at baseline (<2%), we examined the potential association 
between ever exposure to compulsory drug abstinence 
programmes and receptive syringe sharing at baseline. 
Similarly, because the proportion on opioid agonist 
treatment was very low at baseline (3%), we used data 
from an international meta-analysis19 to parameterise 
the effect of this treatment on HIV risk. To account for 
parameter uncertainty, we sampled parameters from 
assigned prior distributions using Latin Hypercube 
Sampling (table 2). 120 000 parameter sets were sampled 
and 204 selected runs producing a log likelihood above 
the 99th percentile were used for the final analyses. 
Most of these runs lay between the 95% confidence 
Intervals (95% CI) of the data (appendix pp 14, 15).
The UCSD and Colegio de la Frontera Norte boards 
approved El Cuete IV, and all participants provided 
written informed consent.
Epidemic modelling analyses
To assess the contribution of incarceration and syringe 
confiscation to the HIV epidemic in people who inject 
drugs with no drug law reform (2012–30), we modelled 
Point estimate (sampled range) Sampling 
distribution
Source
Men Women
Demographic
Rate of exposure to syringe confiscation in past 6 months 
at baseline (per year)
0·26 (0·16–0·36) 0·23 (0·13–0·33) Beta El Cuete IV13
Rate of exiting prison among people who inject drugs 
incarcerated in the past 6 months at baseline (per year)
3·1 (0–7) 2·9 (0–7) Truncated normal El Cuete IV13
Proportion of people who inject drugs incarcerated before 
starting injecting
82% (79–92) 33% (19–61) Fitted values Fitted to El Cuete data using 
cohort model (appendix)
Primary incarceration rate (per year) 0·018(0–0·047) 0·034 (0·001–0·055) Fitted values Fitted to El Cuete data using 
cohort model (appendix)
Reincarceration rate (per year) 0·27 (0·80–0·46) 0·20 (0·03–0·40) Truncated normal El Cuete IV13
Behavioural
Relative change in proportion reporting recent receptive 
syringe sharing among recently released from prison vs 
never or not recently incarcerated
1·30 (1·15–1·46)* 1·30 (1·15–1·46)* Log-normal El Cuete IV13
Relative change in proportion reporting recent receptive 
syringe sharing among recently exposed vs not recently 
exposed to syringe confiscation by the police
1·16 (1·03–1·29)* 1·16 (1·03–1·29)* Log-normal El Cuete IV13
Relative change in proportion reporting recent receptive 
syringe sharing among people who inject drugs ever vs 
never exposed to CAP
1·14 (1·00–1·30)* 1·14 (1·00–1·30)* Log-normal El Cuete IV13
Relative risk of injecting HIV acquisition among people 
who inject drugs on OAT compared to no OAT
0·46 (0·32–0·67) 0·46 (0·32–0·67) Log-normal MacArthur et al19
Rate of OAT cessation (per year) 1 1 Fixed Bukten et al,20 Martin et al21
Data are mean (95% CI). Parameters were allowed to vary within the 95% CI shown in brackets. Additional detail on El Cuete IV data is provided in the appendix. 
LLK=log-likelihood. CAP=compulsory abstinence programme. OAT=opioid agonist treatment. *Adjusted for duration of injection.
Table 1: Key model parameters associated with incarceration and police harassment
Point estimate (95%CI) Distribution used 
for LLK calculation
Source
Men Women
HIV prevalence among people who inject drugs in 2005 2·3% (1–5·3) 2·3% (1–5·3) Beta Frost et al22
HIV prevalence among people who inject drugs in 2006 2·4% (1·3–3.6) 5·4% (1·5-7·8) Beta Strathdee et al23
HIV prevalence among ever incarcerated people who inject drugs in 2011 3·5% (1·7–5·4) 5·2% (1·7-8·8) Beta El Cuete IV13
Relative HIV prevalence among ever versus never incarcerated people who 
inject drugs in 2011
1·1 (0·3–4·7) 3·2 (0·7-15) Normal El Cuete IV13
HIV incidence among people who inject drugs in 2015 (per 100 person-years) 0·5 (0·06–0·9) 1·1 (0·3-1·8) Poisson El Cuete IV13
Proportion of new infections attributable to sexual transmission in 2006 0·45 (0·30–0·60) 0·45 (0·30–0·60) Normal HIV/syphilis 
model (appendix)
Data are mean (95% CI). Parameters were allowed to vary within the 95% CI shown in brackets. Additional detail on El Cuete IV data is provided in the appendix. LLK=log-likelihood. 
*Adjusted for duration of injection.
Table 2: Data used to calibrate the model
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a baseline scenario with no change in incarceration or 
syringe confiscation from 2012 (mandated start of 
the reform). In view of the low proportion on 
ART (<1%), opioid agonist treatment (3%) and recent 
compulsory drug abstinence programmes (<2%) at 
base line, we assumed no coverage of these for the 
baseline scenario.
To estimate the population attributable fraction of 
potential modifiable variables associated with the 
narcomenudeo reform, we assessed the population 
attributable fraction of incarceration and syringe 
confiscation from 2012 until 2030. This was implemented 
by setting incarceration rates to zero and eliminating the 
increased risk in people who inject drugs recently 
incarcerated and recently exposed to syringe confiscation. 
We calculated the relative reduction in the number of 
new infections between 2012 and 2030 in this scenario 
compared to the baseline scenario. Additionally, we 
investigated the population attributable fraction of recent 
incarceration and syringe confiscation in isolation.
To estimate the potential interim effect of the limited 
enforcement of the narcomenudeo reform up to now 
(2012–17), we modelled observed changes in policing 
(ie, syringe confiscation) and recent incarceration since the 
mandated narcomenudeo reform enforcement in 2012 in 
people who inject drugs in the El Cuete cohort. We 
estimated the number of new infections prevented between 
2012 and 2017 compared with the baseline scenario.
It is uncertain how full implementation of the 
narcomenudeo reform could affect the incarceration 
of people who inject drugs, but in 2011, 80% of 
incarcerations in the past 6 months were due to possess-
ing drugs or minor infractions associated with drug use.13 
To estimate the potential future effect of the narcomenudeo 
reform on the HIV epidemic in people who inject drugs 
under different degrees of implemen tation from 2018 
to 2030, we modelled four scenarios that incorporated 
observed changes in recent incar ceration and syringe 
confiscation over 2012 to 2017, assuming these remained 
stable thereafter. The scenarios explored assumed: first, 
no additional changes; second, 80% reduction in in-
carceration rates in people who inject drugs in a limited 
enforcement scenario; third, opioid agonist treatment 
instead of incarceration for drug-related crimes (80% of 
incarcerations), assuming a 53% (95% CI 33–68) reduct-
ion in injecting-related HIV acquisition risk on opioid 
agonist treatment for 1 year on average; and finally, 
compulsory drug abstinence pro grammes instead of 
incarceration for drug-related crimes (80% of incarcer-
ations; table 1, appendix).
Sensitivity analyses exploring a lower reduction in 
incarceration (and associated diversion to opioid agonist 
treatment or compulsory drug abstinence programmes) 
and longer or shorter duration on opioid agonist 
treatment were implemented.
For statistical and epidemic modelling analyses, we 
used SAS (version 9.4) and Matlab R2015b, respectively.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
In 2011, before the narcomenudeo reform, 547 (75%) of 
733 people who inject drugs in the El Cuete cohort in 
Tijuana reported having ever been incarcerated, on 
average five times since starting injecting drugs. People 
who inject drugs recently incarcerated (past 6 months) 
had a relative risk of 1·30 (95% CI 1·15–1·46) of 
receptive syringe sharing compared with those never or 
not recently incarcerated, adjusting for duration of 
injection (table 1). Although the proportion of people 
who inject drugs reporting recent incarceration 
fluctuated around an average of 5·8% between 2013 and 
2016, no trend was observed over time (appendix 
pp 2–5). In 2011, nearly 11% of people who inject drugs 
reported having syringes confiscated by police in the 
past 6 months, an experience associated with a 
1·16 (95% CI 1·03–1·29) relative risk of receptive 
syringe sharing, compared with those not recently 
exposed, adjusting for duration of injection (table 1). A 
decrease in exposure to recent syringe confiscation was 
recorded between 2012 and 2013 and continued to reach 
0% by 2015 (appendix pp 2, 3).
Levels of drug treatment were low and remained 
negligible between 2011 and 2016. The proportion of 
people who inject drugs on opioid agonist treatment 
was 3·1% in 2011, and remained low over time 
(2·2% in 2016). Only 1·4% of people who inject drugs 
reported exposure to compulsory drug abstinence 
programmes in the past 6 months in 2011. Although 
there were spikes (up to 5%) in the proportion of 
people who inject drugs reporting recent exposure in 
2015 and 2016, no trend could be confirmed, so it is 
unclear whether the reform led to a consistent rise in 
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Figure 2: Model projections of HIV infections attributable to incarceration 
and syringe confiscation in people who inject drugs in Tijuana from 2012–30
Boxes represent the 25–75% range, whiskers represent the 2·5–97·5% CI of 
model projections.
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exposure. In 2011, 10·3% of people who inject drugs 
reported ever exposure to compulsory drug abstinence 
programmes, which was associated with a 1·14 (95% CI 
1·00–1·30) relative risk of receptive syringe sharing 
compared with those never exposed, adjusting for 
duration of injection.
Using these findings, modelling suggested that in the 
absence of the narcomenudeo reform from 2012 to 2030, 
10·8% (95% CI 4·8–18·9) of the estimated 1715 (699–3108) 
new HIV infections in people who inject drugs could be 
attributed to incarceration and syringe confiscation, 
corres-ponding to 192 (95% CI 42–464) new infections 
(figure 2). Incarceration alone could contribute 7·1% 
(95% CI 2·5–13·8) of new infections, whereas syringe 
confiscation alone could contribute 3·9% (0·2–9·0) of 
new infections.
The small observed changes in policing experienced by 
people who inject drugs since the narcomenudeo reform 
in 2012 (no incarceration changes, but decrease in 
exposure to recent syringe confiscation by police) has 
probably resulted in a small decrease in HIV incidence, 
averting 1·6% (95% CI 0·2–3·3) of new HIV infections 
in people who inject drugs over this period (2012–17). If 
syringe confiscation is kept at zero but no additional 
changes in narcomenudeo reform implementation 
occur, 5·0% (95% CI 0·7–10·4) of the estimated 
1253 (481–2358) new HIV infections could be averted 
from 2018 to 2030 compared with no reform (figures 3, 4).
If the incarceration rate of people who inject drugs is 
reduced by 80% from 2018 in addition to continued 
elimination of syringe confiscation by police as recorded so 
far, then 8·9% (95% CI 3·8–16·0) of new infections could 
be averted from 2018 to 2030 compared with no reform 
(figures 2, 3). Additionally, if people who inject drugs who 
would have been incarcerated were referred to evidence-
based opioid agonist treatment services, 20·8% (95% CI 
9·9–32·5) of new infections could be averted (figure 3, 4).
Improper reform implementation could limit effect or 
perhaps even cause harm. Modelling predicts that if 
people who inject drugs were sent to compulsory drug 
abstinence programmes instead of prison, this could 
potentially result in more HIV infections compared with 
no reform (–2·2% infections averted from 2018 to 2030 
[95% CI –23·2 to 9·5]) and be accompanied by a rise in 
HIV prevalence (figure 4).
Findings of sensitivity analyses showed that while the 
magnitude of the association varies with lower reductions 
in incarceration and lower or higher opioid agonist 
treatment duration, results do not change qualitatively 
(appendix p 22).
Discussion
As drug policy reform gathers momentum, rigorous 
scientific studies are necessary to assess the public health 
impact of these structural interventions and to improve 
implementation. Our epidemic modelling study is unique 
in that it quantifies the effect of drug-law reform on HIV 
transmission in people who inject drugs. We show that 
syringe confiscation and incarceration could contribute to 
more than 10% of new infections in people who inject 
drugs in Tijuana between 2012 and 2030 and that observed 
reductions in syringe confiscation between 2012 and 2017 
have only prevented a small proportion of new infections. 
Substantial reductions in incarceration (80%) could 
prevent nearly one in ten new infections over the next 
12 years (2018–30) and this would increase to one in 
five new infections if opioid agonist treatment was 
provided to people who inject drugs who would 
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otherwise be incarcerated. Appropriately enforced reform 
could therefore have a substantial effect on the epidemic. 
These findings, while unique in terms of assessing drug 
law reform impact, support previous modelling studies 
indicating that reductions in incarceration could reduce 
HIV and hepatitis C transmission in people who inject 
drugs.2,8,9  The narcomenudeo reform in Mexico carries the 
potential to address structural factors in people who inject 
drugs that increase their HIV risk. Unfortunately, stark 
discrepancies between written laws and policing practices 
in Tijuana have translated into minimal benefits, and 
potential harms.
Our findings show that if people who inject drugs 
were instead referred to compulsory drug-abstinence 
programmes, the main drug-rehabilitation programme 
available in Tijuana, the effect would be smaller and the 
number of new HIV infections could rise. The main 
concern with compulsory treatment is the potential effect 
of coercion on patients’ wellbeing and treatment success. 
In Tijuana, this is compounded by the lack of legal 
specification regarding the type of mandated drug 
treatment. Indeed, interviews in people who inject drugs 
in Tijuana found that none of the compulsory drug 
abstinence programme referrals were legal, and they often 
involved police abuse and were associated with traumatic 
experiences (appendix pp 22, 23).24 Increases in syringe 
sharing in those exposed to compulsory drug-abstinence 
programmes could be the result of poor mental health 
and low self-care after psychological or physical abuses in 
these centres. Compulsory drug-abstinence programmes 
exposure in people who inject drugs in Tijuana was also 
associated with non-fatal overdoses.17 Similarly, studies in 
China and Thailand found positive associations between 
exposure to compulsory drug abstinence programmes 
and drug paraphernalia sharing25 and avoidance of health 
care,26 respectively. By contrast, in settings such as 
Portugal, referral to treatment is recommended but only 
imposed on a case-by-case basis.27
Poor knowledge of the reform and drug laws in Tijuana 
police posed a substantial barrier to reform enforcement. 
In 2015, less than one in ten police officers correctly 
identified the possession threshold for heroin,28 just over 
half correctly recognised syringes to be legal, and two-
thirds reported making at least one arrest for syringe 
possession in the past 6 months. During interviews with 
high-level police, public health, and drug treatment 
sector officials, participants expressed confusion about 
the reform,29 and typically identified mass-media as their 
source of information. No action was taken to develop, 
disseminate or implement reform operating procedures 
(appendix pp 22, 23).29 Between 2015 and 2016, Proyecto 
Escudo, a novel police education programme framed as 
occupational health training, was implemented to assist 
the enforcement of the narcomenudeo reform by shifting 
police knowledge, attitudes, and practices targeting 
people who inject drugs thereby promoting police-public 
health collaboration.15 Preliminary findings suggest 
improved understanding of the legal status of syringe, 
heroin, and marijuana possession, along with better 
attitudes about public health-driven drug law reform.28,30 
Future work should assess the effect of this police 
education programme on HIV transmission in people 
who inject drugs.
Although the promise of police education is encouraging, 
numerous barriers to reform implemen tation exist, includ-
ing conflict between the narcomenudeo’s provisions on 
drugs and the local ordinance prohibiting their public 
consumption or, ambiguously, any deviant behaviour. A 
spectrum of minor infractions, such as sleeping in public, 
loitering, or failure to produce identification are punish-
able. In addition, while the narcomenudeo reform 
depenalises drug possession under a threshold, it allows 
detention (up to 48 h) until determination that the amount 
was below thresholds. These thresholds are very low 
compared with those established in other settings such as 
Portugal, which allow for the possession of quantities 
corresponding to 10 days of personal consumption. Given 
police incentives are based on metrics such as numbers of 
arrests made, these are unlikely to decrease.
Another barrier is the lack of affordable and quality 
drug treatment in Tijuana. Only three evidence-based 
outpatient opioid agonist treatment providers (total 
capacity 800 patients, only 150 subsidised) and one public 
inpatient centre (30 patients capacity) currently operate.31 
These providers charge USD$75–250 per month for 
opioid agonist treatment, unaffordable for most people 
who inject drugs, 75% of whom earn below $200 per 
month.13 While expansion of opioid agonist treatment 
could have synergistic effects on HIV treatment, such as 
improving ART retention and adherence, access to HIV 
services is virtually missing for people who inject drugs 
in Tijuana. Hence, integration of drug treatment and 
HIV services is unfortunately unlikely to be achieved at 
present.
As with other modelling studies, our analysis is 
limited by uncertainty in the underlying data. First, the 
model parameterisation relies partly on self-reported 
behaviours in people who inject drugs subject to social 
desirability bias and recall imprecision. However, the 
El Cuete IV team is highly experienced at interviewing 
people who inject drugs and has developed a trusting 
relationship with the community, so we expect these to 
be minimised. Second, we relied on the model’s capacity 
to capture HIV transmission and incarceration 
dynamics in this population. We modelled multiple 
epidemic trajectories that fit to these data and 
represented uncertainty in our findings. We note that 
we sampled from a wide range of parameter values, 
and despite obtaining a relatively low number of fits 
(n=204), diverse epidemic trajectories were simulated 
propagating underlying parameter uncertainty. Third, 
our analysis focused on two exposures (incarceration 
and syringe confiscation) associated with receptive 
syringe sharing and potentially associated with the 
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narcomenudeo reform. As such, the contribution of 
police or criminal justice exposures was potentially 
underestimated as people who inject drugs report 
multiple forms of police harassment, including bribery, 
beatings and sexual coercion,32 which might be 
associated with HIV risk. Similarly, people who inject 
drugs reported short-term detention, which remains 
legal under the narcomenudeo reform, and which could 
increase HIV risk. Future work should quantify the 
effect of these exposures on HIV, and potential for 
additional reforms to reduce them. Fourth, despite 
observed associations between incarceration and 
policing and syringe sharing, causality still needs to be 
established. Longitudinal analyses examining changes 
in individual risk before, during, and after incarceration 
and before and after police harassment will clarify the 
mechanisms through which these exposures directly or 
indirectly affect risk behaviour. Fifth, we did not study 
the effect of the reform on other health outcomes in 
people who inject drugs or the broader population. 
Future studies could incorporate the potential effect on 
sexual partners of people who inject drugs (not injecting 
themselves) or other outcomes such as trans mission of 
hepatitis C and tuberculosis. We also did not examine 
the cost-effectiveness of the narcomenudeo reform. The 
costs and benefits will be multisectoral, affecting 
security and health expenditure, economic productivity 
and criminal victimisation. While estimating these 
costs was outside the scope of this paper, we discuss key 
elements and data required for an analysis in Tijuana 
(appendix pp 24–28).
In conclusion, our findings show that in the absence 
of a clear implementation strategy at the law enforce ment 
(police reform) and health system (evidence-based 
drug treatment programmes) levels, inadequately or 
improperly implemented drug law reform will have 
minimal or negative public health effects. Our study 
therefore serves as a call to action to countries reforming 
their drug policies to implement monitoring, evaluation, 
and alignment of drug treatment with international 
standards. Indeed, modelling studies such as ours provide 
a useful tool to assess the effect of drug law reform on 
disease epidemics in Mexico and other countries. Further, 
our study supports the need to explore partnerships 
between the objectives of the security sector and the 
imperatives of public health.
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